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Abstract 
Nitroxoline is considered to be an effective treatment for the urinary tract infections. Recently, it has 
been found to be effective against several cancers. However, few studies have examined the anti-tumor 
activity of nitroxoline in bladder cancer. The purpose of the study was to reveal the possible mechanisms 
how nitroxoline inhibited bladder cancer progression. In vitro assay, we demonstrated that nitroxoline 
inhibited bladder cancer cell growth and migration in a concentration-related manner. Western blot 
analysis demonstrated that nitroxoline downregulated the expressions of epithelial mesenchymal 
transition (EMT)-related proteins. Furthermore, treatment with nitroxoline in the C3H/He mice bladder 
cancer subcutaneous model resulted in significant inhibition of tumor growth. Moreover, the percentage 
of myeloid‐derived suppressor cells (MDSC) in peripheral blood cells significantly decreased after 
treatment of nitroxoline. Taken together, our results suggested that nitroxoline may be used as a 
potential drug for bladder cancer. 
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Introduction 
Bladder cancer is the ninth most common 
malignancies and the most common urinary tract 
malignancy in the world [1, 2]. Bladder urothelial 
carcinoma is mainly classified into non-muscular 
invasive bladder cancer (NMIBC) and muscular 
invasive bladder cancer (MIBC). Approximately 80% 
of total bladder cancer cases are NMIBC. 
Transurethral resection of the tumor (TUR) followed 
by Bacillus Calmette-Guérin (BCG) instillation is a 
standard treatment option for NMIBC. However, 
patients with NMIBC have a high recurrence rate and 
20–30% will progress to MIBC. For these reasons, new 
treatment options are needed to prevent recurrence 
and progression. 
Nitroxoline serves as an antibiotic that has been 
used clinically in Europe for decades and have 
showed activity against biofilm infections[3]. The 
current research shows that nitroxoline has a 
significant inhibitory effect on many solid tumors, 
such as myeloma, breast cancer, glioma, pancreatic 
cancer, and prostate cancer, etc.[4-11], but its effect on 
bladder cancer is poorly known. Multiple 
mechanisms have been described as possible modes 
of the antitumor action of nitroxoline, including the 
activation of cell apoptosis[6], downregulation of 
Na/K-ATPase pump and β-catenin[5], and inhibition 
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of angiogenesis through regulating the function of 
MetAP2 [12]. Notably, several studies have 
demonstrated that nitroxoline inhibits tumor cell 
migration and invasion by inhibition of cathepsin B 
activity [13, 14].  
Although no study has shown the effect of 
nitroxoline on immune response, some indirect 
evidence supports the possibility of an association. 
Liang, Y.A etc. suggested that clioquinol is an analog 
of nitroxoline and engaged in regulating the T cell 
activation, proliferation, and apoptosis by inhibition 
of NF-κB function [15]. Several studies have 
demonstrated that nitroxoline can specifically inhibit 
the activity of cathepsin B [14, 16] that may cause the 
inhibition of lymphocyte proliferation and regulate 
immune cell apoptosis [17]. Thus, we assumed that an 
association between nitroxoline and immune 
responses may exist. 
The purpose of this study was to investigate the 
possible mechanism of nitroxoline on bladder cancer. 
Our data showed that nitroxoline could reduce the 
cell viability, induce cell apoptosis and inhibit cell 
migration in bladder cancer. Furthermore, nitroxoline 
induced in vivo tumor growth inhibition and 
decreased levels of MDSCs in a murine xenograft 
model of bladder cancer. Our findings may provide 
novel strategy for bladder cancer treatment. 
Materials and Methods 
Antibodies and reagents 
Nitroxoline was obtained from Jiangsu Asieris 
Pharmaceuticals, Co., Ltd. (Taizhou, Jiangsu, China) 
and was dissolved in phosphate-buffered saline (PBS). 
The following antibodies were used for Western blot 
analysis: N-cadherin (#13116, CST, Billerica, MA, 
USA), Slug (#9585, CST), MMP-2 (#87809, CST), 
MMP-9 (ab38898, Abcam, Cambridge, United 
Kingdom), β-actin (#4970, CST), Bcl-2 (#3498, CST), 
and cleaved caspase-3 (#9664, CST). The following 
antibodies were used for immunohistochemistry and 
flow cytometry: Ki-67 (#12202, CST), CD31 (ab28364, 
Abcam, Cambridge, United Kingdom), MMP-9 
(ab38898, Abcam, Cambridge, United Kingdom), 
FITC-labeled anti-CD11b antibody (553310, BD 
Bioscience, San Jose, CA, USA), PE-labeled anti-Gr-1 
(553128, BD Bioscience). 
Cell lines and cell culture conditions 
Bladder cancer cell lines MBT-2 and J82 were 
purchased from ATCC Company of the United States. 
The cells were maintained in DMEM+10% FBS at 37℃ 
and 5% CO2. The adherent cells were digested with 
trypsin (including EDTA) to form cell suspension, 
washed twice with PBS, and resuspended with fresh 
culture medium. 
XTT viability assay 
Cells were plated onto 96-well plates at 2×103 per 
well. Following cell adherence, cells were treated with 
nitroxoline at concentrations of 0, 1, 5, 10, 20, and 50 
μM, respectively. After nitroxoline treatment for 
different time points, cells were incubated with XTT 
compound (Roche Diagnostics, Indianapolis, IN, 
USA) for 4 hours. The OD value of each well was 
obtained by a microplate reader (model 680; Bio-Rad 
Laboratories, Inc., Hercules, CA, USA). 
Western blot analysis 
Cells were treated with ice-cold lysis buffer 
containing a protease and phosphatase inhibitor 
cocktail (#78410, Thermo Scientific, Waltham, MA, 
USA). Proteins were transferred to PVDF membrane 
by SDS polyacrylamide gel (Bio-Rad, Hercules, CA, 
USA) electrophoresis. The membrane was blocked in 
5% non-fat milk for 1 h at room temperature, followed 
by overnight incubation with the primary antibodies 
at 4°C. After rinsing with TBST, the membranes were 
incubated with second antibodies at room 
temperature for 1 h. Proteins were detected by the 
enhanced chemiluminescence (ECL) kit (Amersham 
Pharmacia Biotech, Chandler, AZ, USA). 
Analysis of apoptosis with Hoechst 33324 by 
fluorescence microscopy 
Cells were seeded in 6-well culture plates. After 
overnight incubation, cells were treated with 
nitroxoline at concentrations of 0, 10, 20 µM, 
respectively. After treatment for 48 hours, apoptosis- 
Hoechst 33324 staining kit (H3570, ThermoFisher 
Scientific) was used to treat cells for 10 minutes. After 
that, cells were washed twice with PBS for 
observation under a fluorescence microscope. 
Wound healing assay 
Cells were seeded in 6-well plate up to 90% 
monolayer confluency. The monolayer of cells was 
wounded across the bottom of the dish using 100 μL 
pipette tip, and the floating cells were washed using 
PBS. After treatment with different concentrations of 
nitroxoline, wound healing was photographed at 0h, 
24h. The degree of wound healing was evaluated as 
this formula: wound healing (%) = (Original wound 
area –wound area at 24 hour)/original wound area × 
100%. 
Migration assay 
After treatment with nitroxoline for 24 hours, 
cells were digested and re-suspended with serum-free 
culture medium. Cells (5 × 104) were cultured in the 
upper chambers of transwell champers (8-μm pore 
size, #3422, Corning, USA); DMEM containing 20% 
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FBS was added to the lower chamber, and the cells 
were incubated for 24 hours at 37℃. Cells attached to 
the upper chamber were wiped with cotton swabs 
and migrated cells on the lower microporous filter 
membrane were fixed with 4% paraformaldehyde for 
15 min, and stained with 0.1% crystal violet for 
30 min. 
Subcutaneous implantation of mouse bladder 
cancer cells into C3H/He mice 
1 x 106 MBT-2 cells suspended in 200µL PBS were 
subcutaneously implanted into the right flank of 
C3H/He mice. After tumor formation, nitroxoline 
were administrated by gavage at 15 mg/kg or 
60mg/kg per mouse five times a week on days 1, 2, 4, 
5, 7, 8, 10, and 11. The tumor growth was measured 
with a caliper every 2~3 days. Tumor weights were 
evaluated on day 12 after the treatments. Animal 
experimental procedures were approved by the ethics 
committee of Okayama University. 
Flow cytometry analysis 
Peripheral blood was obtained from retroorbital 
venous plexus and harvested into tubes containing 
EDTA. Samples were stained with FITC-CD11b and 
PE-Gr-1 antibodies at 4°C for 1 h. Next, stained 
samples were washed with PBS, resuspended in 250 
μL PBS and analyzed by the MACSQuant Analyzer 10 
(Miltenyi Biotec, Cologne, Germany). 
Immunohistochemistry staining 
Tumor tissue section was fixed in formalin 
solution and embedded in paraffin. Then the sections 
were boiled in 10-mM sodium citrate buffer (pH 6.0) 
for 20 min at 120°C in a microwave oven for antigen 
retrieval. Hydrogen peroxide (3%) in methanol was 
used to inactivate endogenous peroxidase activity for 
10 min. Tissue sections were incubated with the 
primary antibody in a humidified chamber overnight 
at 4°C. The sections were washed three times with 
PBS and incubated with Simple StainTM Mouse 
MAX-PO(R) (414341F, Nichirei Bioscience, Inc., 
Tsukiji, Tokyo, Japan). DAB reaction was performed 
using the DAB substrate kits (425312F, Nichirei 
Bioscience, Inc.). 
Statistical analysis 
The analysis was performed using the GraphPad 
Prism software (GraphPad Prism 8). Data were 
presented as mean ± standard deviation (S.D.). 
Statistical differences were analyzed by one-way or 
two-way analysis of variance. P-Values < 0.05 were 
considered statistically significant. 
Results 
Nitroxoline suppresses cell viability and 
induces apoptosis in bladder cancer cells  
XTT assay was performed to determine the effect 
of nitroxoline treatment on the viability of the two 
bladder cancer cell lines (MBT-2 and J82). Nitroxoline 
caused the inhibition of bladder cancer cell viability in 
a concentration (ranging from 1 to 50 µM) and time 
dependent manner (Fig. 1A and B). Moreover, J82 and 
MBT-2 exhibited an IC50 of 9.93 μM, 26.24 μM 
respectively after 48 hours of nitroxoline treatment. 
J82 cells were more sensitive than MBT-2 to 
nitroxoline. Hoechst 33324 staining demonstrated that 
bladder cancer cells treated with 10 or 20 µM 
nitroxoline for 48h presented obvious apoptotic 
morphological changes, such as chromatin 
condensation, nuclear fragmentation and apoptotic 
bodies (Fig. 1C). In MBT-2 cell, the percentage of 
apoptotic cells in nitroxoline-treated groups were 
22.93±2.68% [10 µM] and 42.30±6.77% [20 µM], 
compared with 2.77± 0.41% in control group. In J82 
cell, the percentage of apoptotic cells in the control 
group was only 8.18 ± 2.76%, but the percentage 
increased to 25.92± 3.18% [10 µM] and 77.53± 7.25% [20 
µM] in the nitroxoline-treated groups (Fig. 1D). 
Nitroxoline inhibits the migration of bladder 
cancer cells 
To quantify the effect of nitroxoline on cell 
motility, wound-healing assay was performed using 
the MBT-2 and J82 cells, and photographed at 0h and 
24 h. As shown in Fig. 2A and 2B, bladder cancer cells 
treated with nitroxoline (ranging from 10 to 50 µM) 
filled the wound area (area between the two dotted 
lines) more slowly than those untreated cells, 
indicating that nitroxoline inhibited cancer cell 
migration compared to the control group. 
Similar results were also obtained in transwell assay. 
The numbers of migrating cells in nitroxoline-treated 
group were significantly decreased compared with 
those in the control group (Fig. 2C and D). 
Nitroxoline reverses bladder cancer cells EMT 
and regulates the expression of 
apoptosis-related proteins  
Western blot analysis was used to examine 
expression of EMT-related proteins N-cadherin, slug, 
MMP-2 and MMP-9 in MBT-2 and J82 cells. The 
results demonstrated the reduced expression of 
N-cadherin, slug and MMP-9 in both cell lines, but the 
MMP-2 expression was decreased only in MBT-2 cells 
(Fig. 3A and B). In addition, nitroxoline also reduced 
the expression of the anti-apoptotic protein Bcl-2 as 
well as elevated the expression of the pro-apoptotic 
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protein cleaved Caspase-3 (C-Caspase-3) (Fig. 3C and 
D). 
Therapeutic efficacy of nitroxoline against 
MBT-2 Xenografts 
Mice bearing subcutaneous tumors were treated 
with vehicle or 15mg/kg, 60mg/kg nitroxoline by 
intragastrically administration for 12 days. As shown 
in Fig. 4A, high dosage of nitroxoline exhibited 
suppression of the tumor volume. The tumors weight 
from 60mg/kg nitroxoline-treated group was 
statistically significantly lower than that in the vehicle 
group (0.43±0.20 g vs 1.40±0.53 g; P < 0.05) (Fig. 4B 
and C). 
To detect the expressions of Ki-67 and CD31, we 
performed the immunohistochemistry staining on 
tissue sections of the resected subcutaneous tumor. 
60mg/kg nitroxoline group did exhibit much more 
serious necrotic regions and less cell proliferation 
inside their tumor tissues than vehicle group. The 
expressions of MMP-9 in high dosage group were 
significantly decreased, compared with vehicle group 
(Fig. 4D). 
Nitroxoline significantly reduces the 
percentage of MDSCs in peripheral blood 
To determine if nitroxoline treatment inhibits 
CD11b+Gr-1+MDSC in C3H/He tumor-bearing mice, 
mice were treated by gavage with nitroxoline or PBS 
as a control five times a week on days 1, 2, 4, 5, 7, 8, 10 
and 11. In mice, MDSCs are defined as cells 
co-expressing of the myeloid cell lineage 
differentiation antigen CD11b and Gr-1. In this study, 
MDSCs in peripheral blood cells were labelled with 
FITC-conjugated CD11b and PE-conjugated Gr-1 
antibody. MDSCs are a heterogeneous population of 
myeloid cells that accumulates in many tumor 
models, and can be divided into two subgroups: 
granulocytic and monocytic MDSC. The proportion of 
peripheral blood CD11b+Gr-1+MDSC was assessed by 
flow cytometry. During tumor progression, MDSCs 
were expanded and accumulated in peripheral blood 
derived from bladder cancer mice model in a 
time-dependent manner. After the treatment of 
nitroxoline for 12 days, the percentage of MDSCs 
were significantly decreased in high dosage of 
nitroxoline group compared to PBS-treated C3H/He 
mice (38.06± 5.24% vs. 55.44± 4.58%) (Fig. 5A and B). 
 
 
Figure 1. Nitroxoline suppresses cell viability and induces apoptosis in bladder cancer cells (A and B). Nitroxoline inhibited bladder cancer cell lines MBT-2, and 
J82 cell viability in a concentration and time-dependent manner. Data are presented as mean ± S.D. (N = 5, *P < 0.05 vs. 1 μM). (C). Hoechst 33324 staining. Bladder cancer cells 
were treated with nitroxoline for 48h. The obvious apoptotic morphological changes were observed in the nitroxoline-treated group. (D). The number of apoptosis cells was 
quantified by fluorescence microscope. The differences between the nitroxoline treatment group and control group were significant. Data are presented as mean ± S.D. (N = 3, 
*P < 0.05 vs. control group, #P < 0.05 vs. 10μM group). 
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Figure 2. Nitroxoline inhibits the migration of bladder cancer cells (A and B). Wound healing assay demonstrated that wound closure was inhibited by nitroxoline in 
MBT-2 and J82 cells in a concentration-dependent manner. Cell migration was quantified by measuring wound closure areas. Data are presented as the mean ± S.D. (N = 3, *P 
< 0.05 vs. control group, #P < 0.05 vs. 10μM group, ##P < 0.05 vs. 20μM group). (C and D). Representative images of transwell migration of nitroxoline-treated bladder cancer 
cells. Nitroxoline inhibited the migration of MBT-2 and J82 cells. Data are presented as mean ± S.D. Scale bar, 100 μm (N = 3, *P < 0.05 vs. control group, #P < 0.05 vs. 10μM 
group, ##P < 0.05 vs. 20μM group). 
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Figure 3. Western blot analysis of EMT biomarkers and apoptosis related proteins (A). Bladder cancer cells treated with nitroxoline for 48h expressed reduced 
levels of N-cadherin, Slug, MMP-2 and MMP-9. (B). The expression level of proteins shown in (A) was quantified by ImageJ software, normalized to β-actin, and graphed. (C). 
Nitroxoline decreased the expression of anti-apoptotic protein Bcl-2 and increased the expression of pro-apoptotic protein cleaved caspase-3. (D). The expression level of 
proteins shown in (C) was quantified by ImageJ software, normalized to β-actin, and graphed. β-actin expression was used as an internal control. 
 
Figure 4. Nitroxoline inhibits tumor growth in the MBT-2 Xenografts (A). Tumor growth curves of MBT-2 tumor bearing mice at the indicated days. Data are 
presented as the mean ± S.D. (N = 7, *P < 0.05). (B). Tumors were excised and photographed after 12 days treatment. (C). The weight of tumors was significantly decreased in 
60mg/kg treatment group, compared with that in control treatment. Data are expressed as the mean ± S.D. (N = 5, *P < 0.05). (D). Representative images of 
immunohistochemical staining for Ki-67, CD31 and MMP-9 in tumor sections from xenografts. All pictures are at the same magnification (200×).  
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Figure 5. Nitroxoline significantly reduces the percentage of MDSCs in peripheral blood (A). Flow cytometric analysis of peripheral blood from tumor-bearing 
mice as well as normal mice at the experiment endpoint. (B). The percentage of CD11b+ Gr-1+ MDSCs in peripheral blood was quantified by FACS analysis. The differences 
between 60mg/kg nitroxoline group and control group were significant. Data are presented as mean ± S.D. (N = 3, *P < 0.05, **P < 0.05 vs. control group on day 12). 
 
Discussion 
In this study, we aimed to reveal the possible 
mechanisms how nitroxoline inhibits bladder cancer 
progression. We observed that nitroxoline suppressed 
cell viability and induced apoptosis in bladder cancer 
cells. Nitroxoline inhibited the migration of bladder 
cancer cells. The expressions of epithelial 
mesenchymal transition (EMT)-related proteins were 
detected by western blotting. Nitroxoline reversed 
bladder cancer cells EMT and regulated the 
expression of apoptosis-related proteins. Using the 
C3H/He mice of subcutaneous murine bladder cancer 
(MBT-2) models, we further confirmed that 
nitroxoline was effective in inhibiting tumor growth. 
Importantly, nitroxoline significantly reduced the 
percentage of MDSCs in peripheral blood. Because 
nitroxoline has been used in the treatment of urinary 
tract infection in humans, our finding has the 
potential clinical implication of repurposing it to 
antitumor application.  
It has been reported that nitroxoline results in 
the suppression of Na/K-ATPase pump and 
β-catenin, which is closely related with cell growth, 
migration, invasion, Reactive Oxygen Species (ROS) 
generation and DNA damage response [5]. Our study 
demonstrated that nitroxoline led to significant 
inhibition of cell viability and induced apoptosis of 
bladder cancer cells in vitro. In addition, we found a 
significant downregulation of apoptosis-related 
protein Bcl-2. Both the Bcl-2 family and caspase family 
have been identified as critical factors associated with 
the apoptosis [18]. Caspase-3 was examined by 
western blot analysis and the results showed that 
cleaved caspase-3 was present, suggesting that 
caspase-3 was significantly activated after nitroxoline 
treatment. Some similar studies have shown that 
nitroxoline can exert an antitumor effect by regulating 
the expression of caspase-3, PARP, P53, Bcl-xL, and 
Mcl-1 [7, 11, 19]. These studies suggest that 
nitroxoline induced the growth inhibition of bladder 
cancer cells by the activation of caspase-3, and 
regulation of Bcl-2 family proteins.  
Epithelial-mesenchymal transition (EMT), a 
process by which tumor epithelial cells acquire the 
capability to migrate, participates in cell invasion and 
metastasis [20]. It has been known that matrix 
metalloproteinase-2 (MMP-2) and matrix 
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metalloproteinase-9 (MMP-9) can promote the 
migration of cancer cells and facilitate extracellular 
matrix degradation. Cathepsin B is capable of 
triggering the degradation of tumor stroma and leads 
to the activation of matrix metalloproteinases 
zymogens [21]. Nitroxoline shows inhibitory activity 
against cathepsin B and is involved in degradation of 
extra-cellular membrane proteins [13, 14]. Chan-on 
(2015) reported that nitroxoline significantly 
suppresses the cell migration and decreases the 
expression of MMP-2 and MMP-9 in 
cholangiocarcinoma cells [9]. In this study, our results 
showed that nitroxoline inhibited migration, as 
determined by wound healing and transwell assay. 
We further observed the downregulation of EMT 
markers, namely N-cadherin, Slug, MMP-2 and 
MMP-9. These findings suggest that nitroxoline 
caused inhibition of migration of bladder cancer cells 
via the downregulation of EMT markers, namely 
N-cadherin, Slug, MMP-2 and MMP-9. 
In the model of bladder cancer in vivo, we found 
that nitroxoline treatment (60 mg/kg) exhibited a 
significant anti-tumor effect. Ki-67 expression is a 
well-known marker of active proliferation and poor 
prognosis in bladder cancer. Nitroxoline and its 
analogues have been proved to have antiangiogenic 
potential by inhibiting the enzymatic activity of 
MetAP2 [12]. CD31 is generally used for the 
evaluation of angiogenesis and the high expression 
level implies the activation and proliferation of 
endothelial cells. In this study, we detected the 
decreased expressions of Ki-67 and CD31 in tumor 
tissue. In addition, the altered MMP-9 expressions in 
local tissues were consistent with the protein level of 
MMP-9, suggesting that nitroxoline mediated the cell 
migration through the downregulation of MMP-9. 
Myeloid‐derived suppressor cells (MDSC) are 
myeloid cells, negatively affect other immune cells, 
and particularly result in T-cell exhaustion, leading to 
immune suppression [22, 23]. We demonstrated the 
decreased levels of MDSC in peripheral blood of 
tumor-bearing mice after nitroxoline treatment. This 
indicates that nitroxoline may enhance anti-tumor 
immunity by decreasing the proportion of MDSC. 
Further studies are necessary to identify which type of 
MDSC cell subsets including monocytic MDSC 
(M-MDSC) and granulocytic MDSC (G-MDSC) 
responds to nitroxoline and investigate the changes of 
MDSC in spleen and tumor microenvironment during 
tumor progression. 
 In conclusion, we show that nitroxoline 
suppresses cell viability, migration and induces 
apoptosis in bladder cancer cells. Moreover, 
nitroxoline significantly inhibits tumor growth and 
decreases levels of MDSC in vivo tumor mouse 
models. Considering that nitroxoline are approved by 
the FDA, our findings suggest that nitroxoline may be 
a potential candidate for bladder cancer. 
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